NKGen Biotech shares are trading higher after the company announced FDA clearance of its investigational new drug application for SNKO1 NK cell therapy for treatment of moderate Alzheimer's Disease.
Portfolio Pulse from Benzinga Newsdesk
NKGen Biotech has received FDA clearance for its investigational new drug application for SNKO1 NK cell therapy for the treatment of moderate Alzheimer's Disease. This has led to a rise in the company's stock.
October 24, 2023 | 4:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NKGen Biotech's stock is trading higher after FDA clearance of its new drug application for Alzheimer's treatment.
The FDA clearance of NKGen Biotech's new drug application is a significant regulatory milestone for the company. This approval increases the likelihood of the drug's success in the market, which is reflected in the rise of the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100